Theragen Etex Co Ltd
Company Profile
Business description
Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.
Contact
58, Sandan-ro 68-gil
Danwon-gu, Gyeonggi-do
Ansan-si
KORT: +82 234637111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
214
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,719.71 | 65.46 | 0.86% |
| DAX 40 | 23,600.53 | 113.20 | 0.48% |
| Dow JONES (US) | 45,150.45 | 145.36 | -0.32% |
| FTSE 100 | 9,177.99 | 61.30 | 0.67% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,469.03 | 189.40 | 0.89% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,437.47 | 21.93 | 0.34% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |